<DOC>
	<DOCNO>NCT02826603</DOCNO>
	<brief_summary>Demonstrate superiority secukinumab ustekinumab treatment moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Study Secukinumab Compared Ustekinumab Subjects With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Subjects must give write , sign date informed consent Chronic plaquetype psoriasis present least 6 month randomization Moderate severe plaque psoriasis define randomization : PASI score ≥12 Body Surface Area ( BSA ) affect plaquetype psoriasis ≥10 % IGA mod 2011 ≥3 ( base scale 04 ) Candidate systemic therapy , define psoriasis inadequately control : Topical treatment ( include topical corticosteroid ) and/or Phototherapy and/or Previous systemic therapy Forms psoriasis plaque psoriasis Druginduced psoriasis Ongoing use prohibit treatment Previous exposure secukinumab biologic drug directly target IL17A IL17RA , ustekinumab , therapy target IL12 IL23 Use investigational drug within 5 halflives investigational treatment study drug initiation Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Plaque psoriasis ,</keyword>
	<keyword>secukinumab ,</keyword>
	<keyword>ustekinumab</keyword>
</DOC>